ARS Pharmaceuticals Stock Quote SPRY - Stock Price, News, Charts, Message Board, Trades

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

13.55

Bid

13.00

Ask

13.80

Volume

0.00 Day's Range 0.00

4.64 52 Week Range 18.49

Market Cap

1.317B

Previous Close

13.55

Open

Last Trade

13.69

Last Trade Time

06:33:36

Financial Volume

VWAP

Average Volume (3m)

1,066,985

Shares Outstanding

97,185,475

Dividend Yield

PE Ratio

-24.22

Earnings Per Share (EPS)

-0.56

Revenue

30k

Net Profit

-54.37M

ARS Pharmaceuticals Inc is a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis. The company is developing neffy, an intranasal epinephrine product in clinical development for pa... ARS Pharmaceuticals Inc is a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis. The company is developing neffy, an intranasal epinephrine product in clinical development for patients and their caregivers with Type I allergic reactions including food, medications, and insect bites that could lead to life-threatening anaphylaxis. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

ars-pharma.com

Headquarters

Wilmington, Delaware, USA

Founded

ARS Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker SPRY. The last closing price for ARS Pharmaceuticals was $13.55. Over the last year, ARS Pharmaceuticals shares have traded in a share price range of $ 4.64 to $ 18.49.

ARS Pharmaceuticals currently has 97,185,475 shares outstanding. The market capitalization of ARS Pharmaceuticals is $1.32 billion. ARS Pharmaceuticals has a price to earnings ratio (PE ratio) of -24.22.

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates

Commercial launch of neffy® (epinephrine nasal spray) underway in the United StatesSupplemental NDA for neffy®1mg dose granted priority review by FDA; PDUFA target date set for March 6...

Form 8-K - Current report

ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States

Agreement leverages ALK’s global footprint in developing and commercializing innovative allergy products ARS Pharma to receive an upfront cash payment of $145 million, with total deal...

ARS Pharmaceuticals Announces Conference Call and Webcasts for its Third Quarter 2024 Financial Results and Presentations at Upcoming Conferences

SAN DIEGO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect...

ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

SAN DIEGO, Oct. 24, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect...

Form 4 - Statement of changes in beneficial ownership of securities

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-1.215	-8.22891974263	14.765	15.25	13.15	1317724	13.88580152	CS
4	-2.57	-15.9429280397	16.12	18.49	13.15	1290991	15.20687135	CS
12	-0.15	-1.09489051095	13.7	18.49	11	1066985	14.53099064	CS
26	4.42	48.4118291347	9.13	18.49	7.55	982003	12.82794466	CS
52	8.79	184.663865546	4.76	18.49	4.64	764275	11.12957968	CS
156	8.27	156.628787879	5.28	18.49	2.55	712047	8.48968297	CS
260	8.27	156.628787879	5.28	18.49	2.55	712047	8.48968297	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
WORXSCWorx Corporation	$ 2.03 (107.14%)	15.65M
PETWag Group Company	$ 0.316 (50.40%)	17.62M
AKTSAkoustis Technologies Inc	$ 0.1251 (43.63%)	55.43M
ESGROEnstar Group Ltd	$ 28.00 (40.92%)	28
CCECCapital Clean Energy Carriers Corporation	$ 24.99 (34.72%)	9
WSBFWaterstone Financial Inc	$ 9.00 (-40.98%)	4
TRSTriMas Corporation	$ 15.62 (-40.79%)	3
BCAXBicara Therapeutics Inc	$ 11.00 (-40.15%)	212
PYXSPyxis Oncology Inc	$ 2.40 (-37.17%)	208.06k
XNCRXencor Inc	$ 15.11 (-36.30%)	2
AKTSAkoustis Technologies Inc	$ 0.1251 (43.63%)	55.43M
PETWag Group Company	$ 0.316 (50.40%)	17.62M
WORXSCWorx Corporation	$ 2.03 (107.14%)	15.65M
XTKGX3 Holdings Company Ltd	$ 0.073 (-18.89%)	10.75M
CRKNCrown Electrokinetics Corporation	$ 1.00 (27.28%)	5.39M